Literature DB >> 20479639

The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome.

Anetta Undas1, Krzysztof Nycz, Maciej Pastuszczak, Tomasz Stompor, Krzysztof Zmudka.   

Abstract

Chronic kidney disease (CKD), defined as a decreased estimated glomerular filtration rate (eGFR < 60 ml/min), is an independent risk factor for cardiovascular events. Both acute coronary syndrome (ACS) and end-stage renal disease have been shown to be associated with formation of compact fibrin clots relatively resistant to lysis. The aim of the current study was to evaluate the effect of CKD on fibrin clot properties in patients with ACS. In 30 ACS patients, aged 48-72 years, with CKD and 30 ACS patients with eGFR more than 60 ml/min, we investigated plasma fibrin clot properties using permeation and turbidity assays, including three different clot lysis assays. The ACS patients with eGFR less than 60 ml/min and those with normal filtration rate did not differ with regard to demographics, risk factors, medications and routine laboratory tests, including fibrinogen. The former group had higher plasminogen activator inhibitor-1 (P = 0.002) and tissue-type plasminogen activator (tPA) (P = 0.008). Compared with ACS patients with eGFR more than 60 ml/min, the ACS patients with CKD formed less porous fibrin clots (P = 0.004) and susceptible to fibrinolysis (P < 0.001), had thicker overall fibrin fibers (P = 0.007), earlier onset of fibrin clot formation (P = 0.004) and increased clot mass (P < 0.001). By multiple regression analysis, clot permeability was independently predicted by eGFR (P = 0.0005) and fibrinogen (P = 0.001), whereas the only predictors of lysis time were eGFR (P = 0.006) and tPA (P = 0.002). This study indicates that ACS patients with CKD display unfavorable fibrin clot properties including impaired fibrinolysis, which might contribute to worse outcome in this population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20479639     DOI: 10.1097/MBC.0b013e32833a9035

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  9 in total

1.  Clot Structure: A Potent Mortality Risk Factor in Patients on Hemodialysis.

Authors:  Katharina Schuett; Anna Savvaidis; Sebastian Maxeiner; Katharina Lysaja; Vera Jankowski; Stephan H Schirmer; Nada Dimkovic; Peter Boor; Nadine Kaesler; Friedo W Dekker; Jürgen Floege; Nikolaus Marx; Georg Schlieper
Journal:  J Am Soc Nephrol       Date:  2017-01-05       Impact factor: 10.121

2.  Inhibition of Thrombin-Activated Fibrinolysis Inhibitor Increases Survival in Experimental Kidney Fibrosis.

Authors:  John M Atkinson; Nick Pullen; Michelle Da Silva-Lodge; Lynne Williams; Tim S Johnson
Journal:  J Am Soc Nephrol       Date:  2014-11-19       Impact factor: 10.121

Review 3.  Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy.

Authors:  Constance C F M J Baaten; Jonas R Schröer; Jürgen Floege; Nikolaus Marx; Joachim Jankowski; Martin Berger; Heidi Noels
Journal:  Clin J Am Soc Nephrol       Date:  2021-11-08       Impact factor: 8.237

4.  Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.

Authors:  Tsung-Hsien Lin; Wen-Ter Lai; Ho-Tsung Hsin; Ai-Hsien Li; Chun-Li Wang; Chi-Tai Kuo; Juey-Jen Hwang; Fu-Tien Chiang; Shu-Chen Chang
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

5.  Impact of impaired glomerular filtration rate and revascularization strategy on one-year cardiovascular events in acute coronary syndrome: data from Taiwan acute coronary syndrome full spectrum registry.

Authors:  Tsung-Hsien Lin; Ho-Tsung Hsin; Chun-Li Wang; Wen-Ter Lai; Ai-Hsien Li; Chi-Tai Kuo; Juey-Jen Hwang; Fu-Tien Chiang; Shu-Chen Chang; Chee-Jen Chang
Journal:  BMC Nephrol       Date:  2014-04-23       Impact factor: 2.388

6.  Additive effect of in-hospital TIMI bleeding and chronic kidney disease on 1-year cardiovascular events in patients with acute coronary syndrome: Data from Taiwan Acute Coronary Syndrome Full Spectrum Registry.

Authors:  Tsung-Hsien Lin; Wen-Ter Lai; Chi-Tai Kuo; Juey-Jen Hwang; Fu-Tien Chiang; Shu-Chen Chang; Chee-Jen Chang
Journal:  Heart Vessels       Date:  2014-05-07       Impact factor: 2.037

7.  Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis.

Authors:  Y C Lau; Q Xiong; P Ranjit; G Y H Lip; A D Blann
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

8.  Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy.

Authors:  Wael Sumaya; Lars Wallentin; Stefan K James; Agneta Siegbahn; Katja Gabrysch; Maria Bertilsson; Anders Himmelmann; Ramzi A Ajjan; Robert F Storey
Journal:  Eur Heart J       Date:  2018-04-01       Impact factor: 29.983

9.  Plasma fibrinogen and mortality in patients undergoing peritoneal dialysis: a prospective cohort study.

Authors:  Jing Yu; Tong Lin; Naya Huang; Xi Xia; Jianbo Li; Yagui Qiu; Xiao Yang; Haiping Mao; Fengxian Huang
Journal:  BMC Nephrol       Date:  2020-08-17       Impact factor: 2.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.